new generation of weight management treatments signals a breakthrough in care
Backed by over a century of scientific leadership in obesity and diabetes care, global healthcare company Novo Nordisk is strengthening its commitment to improving treatment for people living with obesity in the Philippines, as a new wave of therapies becomes available to Filipino patients.
Central to this progress are glucagon-like peptide-1 (GLP-1) receptor agonists—medications that mimic a natural hormone in the body responsible for regulating hunger and blood sugar. These treatments help individuals feel fuller for longer, curb cravings, and better control their appetite, while also supporting improved blood sugar management for those with diabetes.
This dual benefit marks a significant shift in how obesity and related conditions are treated—not as matters of willpower, but as chronic diseases requiring medical care.
The rise of GLP-1–based treatments represent one of the most important breakthroughs in metabolic health in recent years. These medicines have, over time, demonstrated substantial and sustained weight loss outcomes in clinical studies—bringing obesity treatment closer to the effectiveness of surgical interventions, but in a less invasive form.
According to the National Library of Medicine, GLP-1 RA medications have revolutionized weight loss and can reduce body weight in obese patients by between 15% and 25% on average after about one year. Their mode of action is to mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism and satiety.
This evolution reflects decades of research into the biology of hunger, hormones, and weight regulation, culminating in therapies that address the root causes of obesity.
“We are entering a new era in obesity care in the country. One that is grounded in science, compassion, and long-term solutions,” said Wei Sun, general manager of Novo Nordisk Philippines. “For many years, people living with obesity have been left with limited options and significant stigma. Today, with advancements in treatments that work with the body’s natural systems, we could transform outcomes for patients across the Philippines.”
Patient safety
As these innovations become more accessible, Novo Nordisk emphasizes the importance of patient safety and proper medical guidance. The company urges patients to seek consultation with qualified healthcare professionals and to use only approved, regulated medicines.
With the growing global demand for weight management treatments, there has also been a rise in compounded or unregulated versions that may not meet the same standards of quality, safety, and efficacy.
“Patient safety must always come first,” Sun added. “We strongly advise against the use of unapproved or compounded alternatives that bypass strict regulatory processes. These products may pose serious health risks and do not offer the same assurance of safety and effectiveness as approved medicines.”
Beyond treatment availability, Novo Nordisk’s initiatives in the Philippines concentrate on raising awareness of obesity as a chronic illness, providing healthcare professionals with up-to-date medical education, and collaborating to increase access to safe, evidence-based care.
No Comments